Bicycle Therapeutics to tackle AMR with government funding

UK biotech company Bicycle Therapeutics is to develop a new class of antibacterial agents to tackle antimicrobial resistance (AMR) after receiving a grant of £496,000 ($640,000) from the government.

The Cambridge-based firm will use its proprietary screening platform to discover novel inhibitors of Penicillin Binding Proteins (PBPs), funded by the UK government as part of its drive to tackle the global threat of superbugs resistant to existing antibiotics.

Article: PMLive